Summary: The Heart of the Matter

Barbara is 72 and sitting in a paper gown when her doctor tells her that her blood pressure is “a little high.” Her cholesterol is borderline. Her EKG looks fine. She has eight minutes left in this appointment, and in those eight minutes, her doctor will weigh a statin against muscle pain that could stop her morning walk, consider pushing her blood pressure target lower knowing the medication may make her dizzy enough to fall, and not have time to explain why her 70-year-old heart works differently than it did at 50. This is not a failure of her doctor. It is a failure of the system that gives him eight minutes.

Even without disease, the cardiovascular system changes with age. Arteries stiffen. The left ventricle thickens. Reserve capacity declines. Heart disease remains the leading cause of death in Americans over 65, with total costs exceeding $174 billion annually in patients 65 and older. Age-adjusted mortality from heart attack dropped more than 60% between 1999 and 2019, but the decline has plateaued, and the improvements have not been shared equally. Black Americans have the highest cardiovascular mortality. Women are diagnosed later with worse outcomes. Geography concentrates death in the Southeast stroke belt and rural areas with fewer cardiologists.

The statin question after 75 is murkier than before it: thinner evidence base, but real modest benefit shown in recent studies, and stopping a working statin carries a 33% higher risk of cardiovascular hospitalization. The blood pressure target debate turned on SPRINT, which showed significant benefit from intensive lowering in older adults but also more fainting, kidney injury, and medication burden. The honest answer is that targets should be individualized, which requires an appointment long enough to figure out which patient is which.

AI-driven risk models are beginning to outperform traditional scoring. Remote cardiac monitoring shows sustained blood pressure improvement at 12 months. The ACCESS model launching in July 2026 creates Medicare’s first dedicated payment pathway for continuous cardiovascular monitoring. These tools are improving detection. Access is uneven, validation across elderly populations incomplete.

The single most powerful cardiovascular intervention requires no prescription: getting up and moving. The full case for exercise comes in this series’ final installment.